CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Nuclera, the biotechnology company enabling access to innovative protein technologies, today announced the publication of research conducted in collaboration with researchers at the University of Cambridge’s Department of Biochemistry, demonstrating a rapid, cell-free approach utilizing proprietary nanodisc technology to produce challenging protein drug-targets for high-resolution structural analysis.The research, published as a preprint on bioRxiv,